RENOVORX INC(NASDAQ:RNXT) stock Fundamental Analysis

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to RNXT. RNXT was compared to 572 industry peers in the Biotechnology industry. While RNXT seems to be doing ok healthwise, there are quite some concerns on its profitability. RNXT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

RNXT had negative earnings in the past year.

RNXT had a negative operating cash flow in the past year.

In the past 5 years RNXT always reported negative net income.

RNXT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

RNXT has a worse Return On Assets (-91.35%) than 72.21% of its industry peers.

RNXT has a Return On Equity of -129.59%. This is in the lower half of the industry: RNXT underperforms 60.71% of its industry peers.

		Industry Rank	Sector Rank
ROA	-91.35%
ROE	-129.59%
ROIC	N/A

ROA(3y)-290.93%

ROA(5y)-248.18%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

RNXT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RNXT has more shares outstanding than it did 1 year ago.

RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

RNXT has an Altman-Z score of -1.84. This is a bad value and indicates that RNXT is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -1.84, RNXT is in line with its industry, outperforming 53.10% of the companies in the same industry.

There is no outstanding debt for RNXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.84

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 5.66 indicates that RNXT has no problem at all paying its short term obligations.

The Current ratio of RNXT (5.66) is comparable to the rest of the industry.

A Quick Ratio of 5.66 indicates that RNXT has no problem at all paying its short term obligations.

RNXT's Quick ratio of 5.66 is in line compared to the rest of the industry. RNXT outperforms 60.00% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.66
Quick Ratio	5.66

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.69% over the past year.

EPS 1Y (TTM)43.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%23.08%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNXT will show a very strong growth in Earnings Per Share. The EPS will grow by 23.63% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y64.78%

EPS Next 2Y28.72%

EPS Next 3Y23.63%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

RNXT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNXT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as RNXT's earnings are expected to grow with 23.63% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.72%

EPS Next 3Y23.63%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RNXT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RENOVORX INC

NASDAQ:RNXT (2/7/2025, 8:00:01 PM)

After market: 1.16 0 (0%)

1.16

-0.3 (-20.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2024-11-13/amc

Earnings (Next)N/A N/A

Inst Owners3.73%

Inst Owner Change0%

Ins Owners1.9%

Ins Owner Change0%

Market Cap27.84M

Analysts82.22

Price Target5.61 (383.62%)

Short Float %0.55%

Short Ratio1.26

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)10.13%

Min EPS beat(2)1.96%

Max EPS beat(2)18.3%

EPS beat(4)3

Avg EPS beat(4)18.18%

Min EPS beat(4)-0.2%

Max EPS beat(4)52.67%

EPS beat(8)5

Avg EPS beat(8)10.1%

EPS beat(12)8

Avg EPS beat(12)6.02%

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-3.3%

EPS NQ rev (1m)-6.89%

EPS NQ rev (3m)-29.16%

EPS NY rev (1m)0%

EPS NY rev (3m)4.17%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.94
P/tB	3.94
EV/EBITDA	N/A

EPS(TTM)-0.58

EYN/A

EPS(NY)-0.38

Fwd EYN/A

FCF(TTM)-0.36

FCFYN/A

OCF(TTM)-0.36

OCFYN/A

SpS0

BVpS0.29

TBVpS0.29

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-91.35%
ROE	-129.59%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-290.93%

ROA(5y)-248.18%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.66
Quick Ratio	5.66
Altman-Z	-1.84

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)43.69%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%23.08%

EPS Next Y64.78%

EPS Next 2Y28.72%

EPS Next 3Y23.63%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y14.21%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y9.77%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y9.77%

OCF growth 3YN/A

OCF growth 5YN/A

RENOVORX INC (RNXT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens